| Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. | |
| | |
MedLine Citation:
|
PMID: 22322558 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The purpose of this study was to determine therapeutic effects and systemic toxicity of 212Pb-trastuzumab in an orthotopic model of human prostate cancer cells in nude mice. TCMC-Trastuzumab was radiolabeled with 212Pb. The 212Pb-trastuzumab generated from the procedure was intact and had high binding affinity with a dissociation constant (of 3.9±0.99 nM. PC-3MM2 cells, which expressed a lower level of HER2 both in culture and in tumors, were used in therapy studies. A single intravenous injection of 212Pb-trastuzumab reduced tumor growth by 60-80%, reduced aortic lymph node metastasis, and prolonged the survival of tumor-bearing mice. Treatment with 212Pb-trastuzumab did not cause significant changes in body weight, serum glutamic pyruvic transaminase (SGPT), blood urea nitrogen (BUN), hematological profiles, and histological morphology of several major organs of tumor-bearing mice. These findings suggest that a systemic delivery of 212Pb-trastuzumab could be an effective modality for management of advanced human prostate cancer. |
| | |
Authors:
|
Zongqing Tan; Pingping Chen; Nathan Schneider; Samuel Glover; Lingling Cui; Julien Torgue; Olivier Rixe; Henry B Spitz; Zhongyun Dong |
Related Documents
:
|
1761348 - Chai-ling-tang (japanese name: sairei-to) as an oral adjuvant. 22901228 - Comparison of serum tumor associated material (tam) with conventional biomarkers in can... 22791818 - Rats deficient for p53 are susceptible to spontaneous and carcinogen-induced tumorigene... 9626928 - Suppression of macrophage activation by peritoneal fluid from patients with endometriosis. 23111378 - Three-dimensional positron emission tomography image texture analysis of esophageal squ... 16273188 - P63 expression in salivary gland tumors: role of deltanp73l in neoplastic transformation. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2012-02-06 |
Journal Detail:
|
Title: International journal of oncology Volume: 40 ISSN: 1791-2423 ISO Abbreviation: Int. J. Oncol. Publication Date: 2012 Jun |
Date Detail:
|
Created Date: 2012-04-09 Completed Date: 2012-07-30 Revised Date: 2013-05-08 |
Medline Journal Info:
|
Nlm Unique ID: 9306042 Medline TA: Int J Oncol Country: Greece |
Other Details:
|
Languages: eng Pagination: 1881-8 Citation Subset: IM |
Affiliation:
|
Division of Hematology-Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH 45267, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Androgens
/
physiology* Animals Antibodies, Monoclonal, Humanized / therapeutic use* Cell Line, Tumor Humans Lead Radioisotopes / therapeutic use* Linear Energy Transfer* Male Mice Mice, Nude Prostatic Neoplasms / metabolism, pathology, radiotherapy* Radioimmunotherapy* Receptor, Epidermal Growth Factor / metabolism Receptor, erbB-2 / metabolism Tumor Burden / radiation effects Xenograft Model Antitumor Assays |
| Chemical | |
Reg. No./Substance:
|
0/Androgens; 0/Antibodies, Monoclonal, Humanized; 0/Lead Radioisotopes; EC 2.7.10.1/ERBB2 protein, human; EC 2.7.10.1/Receptor, Epidermal Growth Factor; EC 2.7.10.1/Receptor, erbB-2; P188ANX8CK/trastuzumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reactivation of latent HIV-1 by a wide variety of butyric acid-producing bacteria.
Next Document: Differential effects of paraoxonase 1 (PON1) polymorphisms on cancer risk: evidence from 25 publishe...